Cytokinetics is playing catch-up with mavacamten, another myosin inhibitor which already has phase 3 results in place showing it can improve patients' heart function and oxygen consumption ...

"The findings of this trial help us understand that obstructive HCM and nonobstructive HCM are two unique diseases," said trial investigator Dr Milind Desai. Topline results were announced from a ...

The drugmaker was supposed to hear back from the FDA on mavacamten at the end of January, but the regulator delayed its deadline to 28 April to allow more time to look at BMS' risk evaluation and ...

In a communication on April 14, 2025, Bristol Myers Squibb said mavacamten did not meet its dual primary endpoints of changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score ...

"In addition to the established efficacy of CAMZYOS, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clinical and real-world data and more ...

In an addendum to a benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) re-examined whether mavacamten has an added benefit over treatment of physician's choice ...

About CAMZYOS (mavacamten) CAMZYOS® (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment of adults with symptomatic New York Heart ...

has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), simplifying treatment for patients and physicians by reducing the required echo ...

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS ® (mavacamten, 2.5 mg, 5 mg, 10 mg ...